Prostate cancer antigen 3 moderately improves diagnostic accuracy in Chinese patients undergoing first prostate biopsy

• DOI: 10.4103/1008-682x.167715
• Publication Date: 2015-10-20T15:37:47Z
• Authors: Ying-Hao Sun; Fu-Bo Wang; Rui Chen; Shan-Cheng Ren; Xiao-Lei Shi; Ya-Sheng Zhu; Wei Zhang; Tai-Le Jing; Chao Zhang; Xu Gao; Jian-Guo Hou; Chuan-Liang Xu
• Keywords: Prostate biopsy

Prostate cancer antigen 3 (PCA3) is a biomarker for diagnosing prostate (PCa) identified in the Caucasian population. We evaluated effectiveness of urinary PCA3 predicting biopsy result 500 men undergoing initial biopsy. The predictive power score was by area under receiver operating characteristic (ROC) curve (AUC) and decision analysis. sufficed to discriminate positive from negative results but not correlated with aggressiveness PCa. ROC analysis showed higher AUC than %fPSA (0.750 vs 0.622, P = 0.046) patients PSA 4.0-10.0 ng ml-1 , PCA3-based model significantly better base model. Decision indicates superior net benefit almost all threshold probabilities, especially probabilities 25%-40% . However, (0.712) (0.698) or PSAD (0.773) >10.0 Our confirmed that RT-PCR-based test moderately improved diagnostic accuracy Chinese first